Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for BAYRY and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BAYRY and 80,000+ other tickers.
See exactly how BAYRY's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BAYRY and 80,000+ other tickers.
Bayer Aktiengesellschaft, commonly known as Bayer AG, functions as a prominent global life sciences company through its various subsidiaries. Its extensive operations are strategically segmented into Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division concentrates on developing and marketing prescription medications, with key areas including cardiology and women's healthcare. It also offers specialized therapeutic solutions for oncology, hematology, and ophthalmology, alongside diagnostic imaging equipment, contrast agents, and advanced cell and gene therapies…
DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer's global drug development expertise with Henry Ford Health's comprehensive clinical research program and its deep connection to the communities it serves. “Clinical trials are often the first opportunity patients have to access cutting-edge treatments,” said Dr. David Lanfear, Chief Scie.
Bayer Aktiengesellschaft remains undervalued despite a strong 18-month rally and ongoing operational improvements. I see upside potential supported by improving EBIT, robust pipeline assets, and technical breakout, though litigation and high debt persist. Litigation settlements and negative free cash flow weigh on the balance sheet, but recent Apollo investment and restructuring efforts provide some relief.
The asset-management firm agreed to buy a minority stake in Bayer's long-acting reversible contraceptives business.
Bayer said on Friday it had secured €3 billion ($3.4 billion) in equity from Apollo-managed funds in a deal tied to its long-acting reversible contraceptives, or LARC, business, aiming to bolster its capital structure while preserving control.
June 30 (Reuters) - Bayer asked Washington to impose duties on glyphosate, the chemical used in the company's weedkiller Roundup, imported from China, saying it was being sold at artificially low prices.